Connection

WILLIAM K PLUNKETT JR to Lymphocytes

This is a "connection" page, showing publications WILLIAM K PLUNKETT JR has written about Lymphocytes.
Connection Strength

1.155
  1. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res. 2003 Aug 01; 9(8):3204-12.
    View in: PubMed
    Score: 0.154
  2. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002 Feb; 1(4):287-94.
    View in: PubMed
    Score: 0.139
  3. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001 Nov; 7(11):3580-9.
    View in: PubMed
    Score: 0.136
  4. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 2001 Apr; 59(4):725-31.
    View in: PubMed
    Score: 0.131
  5. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res. 1996 Oct; 2(10):1731-41.
    View in: PubMed
    Score: 0.096
  6. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56.
    View in: PubMed
    Score: 0.076
  7. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903.
    View in: PubMed
    Score: 0.070
  8. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64.
    View in: PubMed
    Score: 0.064
  9. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
    View in: PubMed
    Score: 0.057
  10. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006 Dec 15; 108(13):4187-93.
    View in: PubMed
    Score: 0.048
  11. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9.
    View in: PubMed
    Score: 0.044
  12. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 Sep 21; 407(6802):390-5.
    View in: PubMed
    Score: 0.032
  13. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1980 Mar; 40(3):588-91.
    View in: PubMed
    Score: 0.030
  14. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem. 1995 Jan 13; 270(2):631-7.
    View in: PubMed
    Score: 0.021
  15. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993 Jan 01; 81(1):143-50.
    View in: PubMed
    Score: 0.018
  16. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
    View in: PubMed
    Score: 0.015
  17. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008 Sep 01; 112(5):1912-22.
    View in: PubMed
    Score: 0.014
  18. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.